Skip to main content
. Author manuscript; available in PMC: 2017 Feb 15.
Published in final edited form as: Mol Cell Endocrinol. 2015 Nov 6;422:31–41. doi: 10.1016/j.mce.2015.11.005

Fig. 2.

Fig. 2

EGF activates the IRE1α and ATF6α arms of the UPR and induces production of the chaperone, BiP. (A) qRT-PCR comparing the effect of EGF on sp-XBP1 mRNA in T47D, MDA MB-468, HCC1954 and MCF10A cells after EGF treatment for 2 h (n = 3; -EGF set to 1). (B) qRT-PCR analysis of sp-XBP1 mRNA in MDA MB-468 breast cancer cells after pre-treating MDA MB-468 cells with erlotinib or with DMSO-vehicle for 30 min, following by treatment with EGF for 2 h (n = 3; -EGF set to 1). (C) Western blot analysis showing full-length ATF6α (p90-ATF6α) and cleaved-ATF6α (p50-ATF6α) in EGF-treated T47D breast cancer cells. The numbers below the gel indicate the ratio of p50-ATF6α/β-actin. (D) qRT-PCR analysis of BiP mRNA in T47D, MDA MB-468, HCC1954 and MCF10A breast cell lines after treatment with EGF for 4 h (n = 3; -EGF set to 1). (E) qRT-PCR analysis of BiP mRNA in MDA MB-468 breast cancer cells after pre-treating MDA MB-468 cells with erlotinib or DMSO vehicle for 30 min, following by treatment with EGF for 4 h (n = 3; -EGF set to 1). (F) Western blot analysis of BiP protein levels in T47D, MDA MB-468 cells treated with EGF. The numbers below the gel are the ratio of BiP/β-actin. Data is the mean ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001.